Neuraceq FDA Approval History
Last updated by Judith Stewart, BPharm on July 14, 2025.
FDA Approved: Yes (First approved March 19, 2014)
Brand name: Neuraceq
Generic name: florbetaben F18
Dosage form: Injection
Company: Life Molecular Imaging, Ltd.
Treatment for: Positron Emission Tomography Imaging
Neuraceq (florbetaben F18) is a radioactive diagnostic agent indicated for PET imaging of the brain to estimate β-amyloid neuritic plaque density.
- Neuraceq is indicated to estimate amyloid beta neuritic plaque density in adults with cognitive impairment for:
- Evaluation of Alzheimer’s disease (AD) and other causes of cognitive decline.
- Selection of patients who are indicated for amyloid beta-directed therapy as described in the prescribing information of the therapeutic products.
Development timeline for Neuraceq
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.